Your browser doesn't support javascript.
loading
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
Fleischmann, Roy; Mysler, Eduardo; Bessette, Louis; Peterfy, Charles G; Durez, Patrick; Tanaka, Yoshiya; Swierkot, Jerzy; Khan, Nasser; Bu, Xianwei; Li, Yihan; Song, In-Ho.
Afiliação
  • Fleischmann R; Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA rfleischmann@arthdocs.com.
  • Mysler E; Organización Médica de Investigación, Buenos Aires, Argentina.
  • Bessette L; Department of Medicine, Laval University, Quebec City, Quebec, Canada.
  • Peterfy CG; Spire Sciences Inc, Boca Raton, Florida, USA.
  • Durez P; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium.
  • Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Swierkot J; Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
  • Khan N; AbbVie Inc, North Chicago, Illinois, USA.
  • Bu X; AbbVie Inc, North Chicago, Illinois, USA.
  • Li Y; AbbVie Inc, North Chicago, Illinois, USA.
  • Song IH; AbbVie Inc, North Chicago, Illinois, USA.
RMD Open ; 8(1)2022 02.
Article em En | MEDLINE | ID: mdl-35121639

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: RMD Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: RMD Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos